Avilex Pharma

 

Avilex Pharma is a spin out from the University of Copenhagen, founded by
Professor Kristian Strømgaard and Dr Anders Bach of the Department of Drug Design and Pharmacology,
with seed investment from Novo Seeds (part of Novo A/S).

 

Avilex Pharma is developing novel inhibitors of PDZ domains to target a range of unmet medical needs.

 

 

 

For further information, please contact

Professor Kristian Strømgaard, CEO

kristian.stromgaard@avilexpharma.com

+45 3533 6114

 

 

 

Press Release Copenhagen, April 15th, 2013 (English, Danish)